Prostate-specific membrane antigen targeted, glutathione-sensitive nanoparticles loaded with docetaxel and enzalutamide for the delivery to prostate cancer

References

• A safety and efficacy study of oral MDV3100 in chemotherapy-naïve patients with progressive metastatic prostate cancer (PREVAIL) (NCT01212991). (2014) Available at: http://clinicaltrials.gov/ct2/show/NCT01212991 [last accessed 9 Feb 2014].
   Google Scholar
• Afsharzadeh M, Hashemi M, Babaei M, et al. (2020). PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells. J Cell Physiol 235:4618–30.
   PubMed Web of Science ®Google Scholar
• Al-Dulimi A, Al-Saffar A, Sulaiman G, et al. (2020). Immobilization of l-asparaginase on gold nanoparticles for novel drug delivery approach as anti-cancer agent against human breast carcinoma cells. J Mater Res Technol 9:15394–411.
   Google Scholar
• Argenziano M, Lombardi C, Ferrara B, et al. (2018). Glutathione/pH-responsive nanosponges enhance strigolactone delivery to prostate cancer cells. Oncotarget 9:35813–29.
   PubMedGoogle Scholar
• Berthold DR, Pond GR, Soban F, et al. (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26:242–5.
   PubMed Web of Science ®Google Scholar
• Cohen L, Assaraf YG, Livney YD. (2021). Novel selectively targeted multifunctional nanostructured lipid carriers for prostate cancer treatment. Pharmaceutics 14:88.
   PubMed Web of Science ®Google Scholar
• Conte C, Mastrotto F, Taresco V, et al. (2018). Enhanced uptake in 2D- and 3D- lung cancer cell models of redox responsive PEGylated nanoparticles with sensitivity to reducing extra- and intracellular environments. J Control Release. 277:126–41.
   PubMed Web of Science ®Google Scholar
• Duan W, Liu Y. (2018). Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib. Drug Des Devel Ther 12:2149–61.
   PubMed Web of Science ®Google Scholar
• El-Sayed A, Futaki S, Harashima H. (2009). Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. 11:13–22.
   Google Scholar
• Fizazi K, Scher HI, Miller K, et al. (2014). Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol 15:1147–56.
   PubMed Web of Science ®Google Scholar
• Guan Q, Sun D, Zhang G, et al. (2016). Docetaxel-loaded self-assembly stearic acid-modified Bletilla striata polysaccharide micelles and their anticancer effect: preparation, characterization, cellular uptake and in vitro evaluation. Molecules 21:1641.
   PubMed Web of Science ®Google Scholar
• Gunaseelan S, Gunaseelan K, Deshmukh M, et al. (2010). Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs. Adv Drug Deliv Rev 62:518–31.
   PubMed Web of Science ®Google Scholar
• Hong Y, Che S, Hui B, et al. (2019). Lung cancer therapy using doxorubicin and curcumin combination: Targeted prodrug based, pH sensitive nanomedicine. Biomed Pharmacother 112:108614.
   PubMed Web of Science ®Google Scholar
• Huang H, Dong Y, Zhang Y, et al. (2019). GSH-sensitive Pt(IV) prodrug-loaded phase-transitional nanoparticles with a hybrid lipid-polymer shell for precise theranostics against ovarian cancer. Theranostics 9:1047–65.
   PubMed Web of Science ®Google Scholar
• Jabir M, Sahib UI, Taqi Z, et al. (2020). Linalool-loaded glutathione-modified gold nanoparticles conjugated with CALNN peptide as apoptosis inducer and NF-κB translocation inhibitor in SKOV-3 cell line. Int J Nanomedicine 15:9025–47.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM. (2011). Global cancer statistics. CA Cancer J Clin 61:69–90.
   PubMed Web of Science ®Google Scholar
• Jiang W, Chen J, Gong C, et al. (2020). Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy. J Nanobiotechnology 18:50.
   PubMed Web of Science ®Google Scholar
• Juang V, Chang CH, Wang CS, et al. (2019). pH-responsive PEG-shedding and targeting peptide-modified nanoparticles for dual-delivery of irinotecan and microRNA to enhance tumor-specific therapy. Small 15:e1903296.
   PubMed Web of Science ®Google Scholar
• Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, et al. (2013). PROSTY study group. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol. 14:117–24.
   PubMed Web of Science ®Google Scholar
• Kim D, Park C, Meghani NM, et al. (2020). Utilization of a fattigation platform gelatin-oleic acid sodium salt conjugate as a novel solubilizing adjuvant for poorly water-soluble drugs via self-assembly and nanonization. Int J Pharm 575:118892.
   PubMedGoogle Scholar
• Li F, Mei H, Gao Y, et al. (2017). Co-delivery of oxygen and erlotinib by aptamer-modified liposomal complexes to reverse hypoxia-induced drug resistance in lung cancer. Biomaterials 145:56–71.
   PubMed Web of Science ®Google Scholar
• Li J, Djenaba JA, Soman A, et al. (2012). Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001-2007. Prostate Cancer 2012:691380.
   PubMedGoogle Scholar
• Li K, Dong W, Qiu L, et al. (2019). A new GSH-responsive prodrug of 5-aminolevulinic acid for photodiagnosis and photodynamic therapy of tumors. Eur J Med Chem 181:111582.
   PubMed Web of Science ®Google Scholar
• Liu J, Cheng H, Han L, et al. (2018). Synergistic combination therapy of lung cancer using paclitaxel- and triptolide-coloaded lipid-polymer hybrid nanoparticles. Drug Des Devel Ther 12:3199–209.
   PubMed Web of Science ®Google Scholar
• Marín-Aguilera M, Reig Ò, Milà-Guasch M, et al. (2019). The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer. Int J Cancer 145:1970–81.
   PubMed Web of Science ®Google Scholar
• Mirhadi E, Mashreghi M, Faal Maleki M, et al. (2020) Redox-sensitive nanoscale drug delivery systems for cancer treatment. Int J Pharm 589:119882.
   PubMedGoogle Scholar
• Nagesh PKB, Johnson NR, Boya VKN, et al. (2016). PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer. Colloids Surf B Biointerfaces 144:8–20.
   PubMed Web of Science ®Google Scholar
• Nan Y. (2019). Lung carcinoma therapy using epidermal growth factor receptor-targeted lipid polymeric nanoparticles co-loaded with cisplatin and doxorubicin. Oncol Rep 42:2087–96.
   PubMed Web of Science ®Google Scholar
• Pang J, Xing H, Sun Y, et al. (2020). Non-small cell lung cancer combination therapy: hyaluronic acid modified, epidermal growth factor receptor targeted, pH sensitive lipid-polymer hybrid nanoparticles for the delivery of erlotinib plus bevacizumab. Biomed Pharmacother 125:109861.
   PubMed Web of Science ®Google Scholar
• Phan UT, Nguyen KT, Vo TV, Duan W, et al. (2016). Investigation of fucoidan-oleic acid conjugate for delivery of curcumin and paclitaxel. Anticancer Agents Med Chem 16:1281–7.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. (2012). AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–97.
   PubMed Web of Science ®Google Scholar
• Sonkusre P, Nanduri R, Gupta P, Cameotra SS. (2014). Improved extraction of intracellular biogenic selenium nanoparticles and their specificity for cancer chemoprevention. J Nanomed Nanotechnol 05:194.
   Google Scholar
• Sulaiman GM, Waheeb HM, Jabir MS, et al. (2020). Hesperidin loaded on gold nanoparticles as a drug delivery system for a successful biocompatible, anti-cancer, anti-inflammatory and phagocytosis inducer model. Sci Rep. Jun 910:9362.
   PubMed Web of Science ®Google Scholar
• Tan S, Wang G. (2017). Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo. Drug Des Devel Ther 11:3519–29.
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, et al. (2004). TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–12.
   PubMed Web of Science ®Google Scholar
• Wang J, Su G, Yin X, et al. (2019) Non-small cell lung cancer-targeted, redox-sensitive lipid-polymer hybrid nanoparticles for the delivery of a second-generation irreversible epidermal growth factor inhibitor-Afatinib: in vitro and in vivo evaluation. Biomed Pharmacother 120:109493.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zang A, Wei Y, et al. (2020). Hyaluronic acid capped, irinotecan and gene co-loaded lipid-polymer hybrid nanocarrier-based combination therapy platform for colorectal cancer. Drug Des Devel Ther 14:1095–105.
   PubMed Web of Science ®Google Scholar
• Wu R, Zhang Z, Wang B, et al. (2020). Combination chemotherapy of lung cancer – co-delivery of docetaxel prodrug and cisplatin using aptamer-decorated lipid-polymer hybrid nanoparticles. Drug Des Devel Ther 14:2249–61.
   PubMed Web of Science ®Google Scholar
• Xu C, Song RJ, Lu P, et al. (2018). pH-triggered charge-reversal and redox-sensitive drug-release polymer micelles codeliver doxorubicin and triptolide for prostate tumor therapy. Int J Nanomedicine 13:7229–49.
   PubMed Web of Science ®Google Scholar
• Xu Z, Liu S, Kang Y, Wang M. (2015). Glutathione- and pH-responsive nonporous silica prodrug nanoparticles for controlled release and cancer therapy. Nanoscale 7:5859–68.
   PubMed Web of Science ®Google Scholar
• Yan J, Wang Y, Zhang X, et al. (2016). Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo. Drug Deliv 23:1757–62.
   PubMed Web of Science ®Google Scholar
• Yu W, Liu C, Liu Y, et al. (2010). Mannan-modified solid lipid nanoparticles for targeted gene delivery to alveolar macrophages. Pharm Res 27:1584–96. Epub 2010 Apr 27. PMID: 20422265.
   PubMed Web of Science ®Google Scholar
• Zhang T, Ma J, Li C, et al. (2017). Core–shell lipid polymer nanoparticles for combined chemo and gene therapy of childhood head and neck cancers. Oncol Rep 37:1653–61.
   PubMed Web of Science ®Google Scholar
• Zhu B, Yu L, Yue Q. (2017). Co-delivery of vincristine and quercetin by nanocarriers for lymphoma combination chemotherapy. Biomed Pharmacother 91:287–94.
   PubMed Web of Science ®Google Scholar